MARTINSRIED/MUNICH, Germany & PRINCETON, N.J.--(BUSINESS WIRE)--GPC Biotech AG (Frankfurt Stock Exchange: GPC, NASDAQ: GPCB) today reported that new pre-clinical data on RGB-286638, the Company’s multi-targeted protein kinase inhibitor, were presented at the 50th American Society of Hematology (ASH) Annual Meeting in San Francisco, California in a poster entitled, “RGB-286638, a Novel Multi-Targeted Small Molecule Inhibitor, Induces Multiple Myeloma (MM) Cell Death through Abrogation of CDK-Dependent and Independent Survival Mechanisms” (Poster Board II-853). The data presented demonstrate that, in a mouse tumor model, RGB-286638 inhibits the growth of multiple myeloma tumors and prolongs survival. Additionally, RGB-286638 has been shown to trigger apoptosis (programmed cell death) in multiple myeloma cells, including those cells that are resistant to drugs commonly used to treat this form of cancer. The data were presented by researchers at the Dana-Farber Cancer Institute and the Massachusetts General Hospital Cancer Center (MGH), Boston, Massachusetts.
